These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 10649723)

  • 1. In vitro and in vivo generation and kinetics of glycosylation products in peritoneal dialysis effluents.
    Yokota S; Kumano K; Hyodo T; Sakai T; Izumi G; Hashimoto A; Shibata K; Wang H
    Adv Perit Dial; 1998; 14():195-9. PubMed ID: 10649723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic analysis of furosine and pentosidine in CAPD patients.
    Kumano K; Yokota S; Sakai T; Kobayashi N; Yoshida A; Yoshihara T; Shibata K; Izumi G; Wang H
    Adv Perit Dial; 1997; 13():53-7. PubMed ID: 9360651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.
    Ueda Y; Miyata T; Goffin E; Yoshino A; Inagi R; Ishibashi Y; Izuhara Y; Saito A; Kurokawa K; Van Ypersele De Strihou C
    Kidney Int; 2000 Dec; 58(6):2518-24. PubMed ID: 11115086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
    Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
    Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.
    Friedlander MA; Wu YC; Elgawish A; Monnier VM
    J Clin Invest; 1996 Feb; 97(3):728-35. PubMed ID: 8609229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Asymmetric Dimethylarginine and Pentosidine in Dialysis Effluent of Peritoneal Dialysis Patients -A possible intraperitoneal crosstalk between asymmetric dimethylarginine and advanced glycation end products in peritoneal dialysis patients.
    Ishida M; Kakuta T; Miyakogawa T; Tatsumi R; Matsumoto C; Fukagawa M
    Tokai J Exp Clin Med; 2016 Jun; 41(2):97-100. PubMed ID: 27345001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions.
    Ho-dac-Pannekeet MM; Weiss MF; de Waart DR; Erhard P; Hiralall JK; Krediet RT
    Perit Dial Int; 1999; 19 Suppl 2():S68-74. PubMed ID: 10406497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the peritoneal dialysis prescription on pentosidine in children.
    Bayazit AK; Vogt BA; Dell KM; Davis ID; Noyan A; Anarat A; Avner ED; Erhard P; Weiss MF
    Pediatr Nephrol; 2003 Oct; 18(10):1049-54. PubMed ID: 12898376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
    Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
    Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis.
    Tauer A; Knerr T; Niwa T; Schaub TP; Lage C; Passlick-Deetjen J; Pischetsrieder M
    Biochem Biophys Res Commun; 2001 Feb; 280(5):1408-14. PubMed ID: 11162688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation.
    Park MS; Kim JK; Holmes C; Weiss MF
    Perit Dial Int; 2000; 20 Suppl 5():S33-8. PubMed ID: 11229610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
    van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
    Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of N(epsilon)-(carboxymethyl)lysine generation by the antioxidant N-acetylcysteine.
    Nakayama M; Izumi G; Nemoto Y; Shibata K; Hasegawa T; Numata M; Wang K; Kawaguchi Y; Hosoya T
    Perit Dial Int; 1999; 19(3):207-10. PubMed ID: 10433156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.
    le Poole CY; van Ittersum FJ; Valentijn RM; Teerlink T; Lindholm B; Ter Wee PM; Schalkwijk CG
    Perit Dial Int; 2012; 32(1):45-54. PubMed ID: 21632443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced glycation endproducts in the skin and peritoneum.
    Shaw S; Akyol M; Bell J; Briggs JD; Dominiczak MH
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1061-8. PubMed ID: 9846888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliable determination of furosine in human serum and dialysate proteins by high-performance liquid chromatography.
    Wu YC; Monnier V; Friedlander M
    J Chromatogr B Biomed Appl; 1995 May; 667(2):328-32. PubMed ID: 7663707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term increase of glucose concentration in PDS results in extensive removal and high glycation level of vital proteins during continuous ambulatory peritoneal dialysis.
    Pešić I; Dihazi GH; Müller GA; Jahn O; Hoffmann M; Eltoweissy M; Koziolek M; Dihazi H
    Nephrol Dial Transplant; 2011 Aug; 26(8):2674-83. PubMed ID: 21285129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
    Zeier M; Schwenger V; Deppisch R; Haug U; Weigel K; Bahner U; Wanner C; Schneider H; Henle T; Ritz E
    Kidney Int; 2003 Jan; 63(1):298-305. PubMed ID: 12472796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end product free adducts are cleared by dialysis.
    Agalou S; Ahmed N; Thornalley PJ; Dawnay A
    Ann N Y Acad Sci; 2005 Jun; 1043():734-9. PubMed ID: 16037300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage.
    Nakamura S; Niwa T
    J Am Soc Nephrol; 2005 Jan; 16(1):144-50. PubMed ID: 15563557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.